The global aminoglycosides market size accounted for USD 7.55 billion in 2025 and is forecasted to hit around USD 13.1 billion by 2034, representing a CAGR of 6.32% from 2025 to 2034. The Asia Pacific market size was estimated at USD 2.72 billion in 2025 and is expanding at a CAGR of 6.44% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Aminoglycosides Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Aminoglycosides Market Revenue and Volume, by Product
8.1.1 Neomycin
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Tobramycin
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Gentamicin
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Amikacin
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Paromomycin
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Streptomycin
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Kanamycin
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Others
8.1.8.1. Market Revenue and Volume Forecast
9.1. Aminoglycosides Market Revenue and Volume, by Route of Administration
9.1.1. Injectable
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Feed
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Intra-mammary
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Topical
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast
10.1. Aminoglycosides Market Revenue and Volume, by Application
10.1.1. Veterinary
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Skin Infection
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Respiratory diseases
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. UTI & Pelvic Diseases
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Other diseases
10.1.5.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product
11.1.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.3. Market Revenue and Volume Forecast, by Application
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.4.3. Market Revenue and Volume Forecast, by Application
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.5.3. Market Revenue and Volume Forecast, by Application
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product
11.2.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.3. Market Revenue and Volume Forecast, by Application
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.4.3. Market Revenue and Volume Forecast, by Application
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.5.3. Market Revenue and Volume Forecast, by Application
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.6.3. Market Revenue and Volume Forecast, by Application
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.2.7.3. Market Revenue and Volume Forecast, by Application
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product
11.3.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.3. Market Revenue and Volume Forecast, by Application
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.4.3. Market Revenue and Volume Forecast, by Application
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.5.3. Market Revenue and Volume Forecast, by Application
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.6.3. Market Revenue and Volume Forecast, by Application
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.3.7.3. Market Revenue and Volume Forecast, by Application
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product
11.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.3. Market Revenue and Volume Forecast, by Application
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.4.3. Market Revenue and Volume Forecast, by Application
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.5.3. Market Revenue and Volume Forecast, by Application
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.6.3. Market Revenue and Volume Forecast, by Application
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration
11.4.7.3. Market Revenue and Volume Forecast, by Application
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product
11.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.3. Market Revenue and Volume Forecast, by Application
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.4.3. Market Revenue and Volume Forecast, by Application
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration
11.5.5.3. Market Revenue and Volume Forecast, by Application
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck & Co., Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Teva Pharmaceutical Industries
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cipla Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sun Pharmaceutical Industries
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lupin Limited
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Aurobindo Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fresenius Kabi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Viatris Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample